Necrosis News and Research

RSS

New signaling pathway discovery sheds light on chronic dermatitis

A new signaling pathway, which is important for the regulation of the immune response and inflammation, was discovered by an international team of scientists led by prof Ivan Dikic from the Goethe University, Frankfurt, Germany.

1 Apr 2011

Essential protein linked to TNF induced inflammation

SCIENTISTS have discovered an essential protein that controls inflammation induced by 'tumour necrosis factor' (TNF) - an important part of the body's defences against infection and a driver of cancer-associated inflammation, according to research published in Nature today (Wednesday).

31 Mar 2011

Researchers create new computational model to understand animal cell behavior

Biological systems, including cells, tissues and organs, can function properly only when their parts are working in harmony. These systems are often dauntingly complex: Inside a single cell, thousands of proteins interact with each other to determine how the cell will develop and respond to its environment.

24 Mar 2011

Decision Resources: 68% of gastroenterologists select Remicade for Crohn's treatment

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that more than two-thirds of surveyed gastroenterologists selected Centocor Ortho Biotech/Merck & Co./Mitsubishi Tanabe's Remicade as the most efficacious therapy for Crohn's disease, when compared to other currently available agents.

24 Mar 2011

More sensitive test to detect protein troponin associated with increased diagnosis of heart attacks

In patients with a suspected acute coronary syndrome (ACS; such as heart attack or unstable angina), use of a more sensitive test to detect the protein troponin in blood was associated with increased diagnosis of a heart attack and improved identification of patients at high risk of another heart attack and death in the following year, according to a study in the March 23/30 issue of JAMA.

23 Mar 2011

Otelixizumab Phase 3 DEFEND-1 study in new-onset autoimmune type 1 diabetes does not meet primary endpoint

Tolerx, Inc. and GlaxoSmithKline (GSK) today announced that the Phase 3 DEFEND-1 study of otelixizumab, an investigational humanized anti-CD3 monoclonal antibody, did not meet the primary efficacy endpoint of change in C-peptide at month 12 in patients with new-onset autoimmune type 1 diabetes.

11 Mar 2011

Researchers create protein molecule for new anti-inflammatory therapies

Researchers from across multiple disciplines at NYU Langone Medical Center created a new protein molecule derived from the growth factor progranulin may provide the basis for new therapies in inflammatory diseases, such as rheumatoid arthritis, according to a study published in the March 10, 2011 issue of Science.

11 Mar 2011

Despite aspirin therapy, specific inflammatory pathways may influence risk of colorectal cancer

The reduced risk of colorectal cancer associated with taking aspirin or other nonsteroidal anti-inflammatory drugs may be confined to individuals already at risk because of elevations in a particular inflammatory factor in the blood.

10 Mar 2011

Blood biomarker may help decide intake of aspirin or NSAIDs for reduction of cancer risk

The reduced risk of colorectal cancer associated with taking aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) may be confined to individuals already at risk because of elevations in a particular inflammatory factor in the blood.

10 Mar 2011

Research shows how tubercle bacterium manages to survive inside body's macrophage cells

Tuberculosis kills two million people each year and is once again gaining ground also in Sweden and other Western countries. Researchers at Linköping University in Sweden are now presenting new findings that show how the tubercle bacterium manages to survive inside the body's macrophage cells in order eventually to blow them up and spread their infection.

9 Mar 2011

Recent rituximab trial with TNF inhibitors reports no new safety risks in patients with RA

A recent trial of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis found the safety profile to be consistent with other RA trials with TNF inhibitors.

8 Mar 2011

Executioner enzyme may short circuit second form of cell death

An enzyme viewed as an executioner, because it can push cells to commit suicide, may actually short circuit a second form of cell death, researchers at Emory University School of Medicine have discovered.

4 Mar 2011

FADD protein discovery can lead to better cancer and autoimmune disease drugs

Reporting in Nature, scientists from Thomas Jefferson University have determined that a single protein called FADD controls multiple cell death pathways, a discovery that could lead to better, more targeted autoimmune disease and cancer drugs.

3 Mar 2011

Scientists provide new insight into mechanisms controlling programmed cell death pathways

Work led by St. Jude Children's Research Hospital investigators provides fresh insight into mechanisms controlling programmed cell death pathways and offers new targets in the fight against cancer and virus-infected cells

3 Mar 2011

Experimental drug may help preserve neurological function in survivors of sudden cardiac arrest

An experimental drug that targets a brain system that controls inflammation might help preserve neurological function in people who survive sudden cardiac arrest, new research suggests.

2 Mar 2011

Phase I/II safety, efficacy data for Bellicum's BPX-101 presented at 2011 Genitourinary Cancers Symposium

Bellicum Pharmaceuticals, Inc. today announced the presentation of Phase I/II safety and efficacy data for BPX-101, a novel drug-activated dendritic cell vaccine for metastatic castrate resistant prostate cancer (mCRPC), in three separate posters at the 2011 Genitourinary Cancers Symposium held in Orlando, Florida on February 17 – 19, 2011.

19 Feb 2011

JDR releases research report on Osteonecrosis of the jaw

Osteonecrosis of the jaw is a debilitating bone condition that affects the jaws and occurs as a result of reduced local blood supply to the bone. The literature in this area has been severely limited since most investigations cannot evaluate sufficient numbers of afflicted individuals to accurately determine the incidence of the disease and associated risk factors.

14 Feb 2011

Cardiac enzyme elevations following CABG surgery is associated with worse prognosis

Patients who underwent coronary artery bypass graft surgery and had elevated levels of the cardiac enzymes creatine kinase or troponin in the 24 hours following surgery had an associated intermediate and long-term increased risk of death, according to a study in the February 9 issue of JAMA.

9 Feb 2011

Study finds contradictory role of RIP1 protein in the liver during sepsis

Researchers from Rhode Island Hospital have identified a protein that plays a dual role in the liver during sepsis. The protein, known as RIP1, acts both as a "death switch" and as a pro-survival mechanism. The ability to identify the triggers for these functions may play a key role in treating sepsis in the future. The study is published online in advance of print in the journal Shock.

3 Feb 2011

Research identifies potential reversibility of chronic neurologic disability in stroke survivors

A breakthrough in stroke research identifying the potential reversibility of chronic neurologic disability in stroke survivors has published today. In the February 1, 2011 issue of the journal CNS Drugs the first human results of a new method of targeting chronic brain inflammation years after stroke are reported.

2 Feb 2011